The FDA approved Zelboraf (vemurafenib) for the rare blood cancer, Erdheim-Chester disease with BRAF V600 mutation, adding to an existing use in late-stage melanoma. This is the first drug ...

Plexxikon had great expectations for Zelboraf when it first reached the market, pegging peak sales at around $700 million a year, but it never reached those heights with annual sales in the region ...